Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Schrodinger, Inc. - Common Stock (NQ:SDGR)

21.12 +0.16 (+0.76%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Schrodinger, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Receives Fast Track Designation for SGR-1505 for the Treatment of Relapsed/Refractory Waldenström Macroglobulinemia
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
Via ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Commercial Officer
From Schrödinger
Via Business Wire
Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing
From Schrödinger
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Schrödinger, Inc. - SDGR
From Pomerantz LLP
Via GlobeNewswire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger to Present at Jefferies Global Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Announces CFO Appointment
From Schrödinger
Via Business Wire
Schrödinger to Present Phase 1 Clinical Data on MALT1 Inhibitor SGR-1505 at EHA Annual Congress and International Conference on Malignant Lymphoma
From Schrödinger
Via Business Wire
Schrödinger Reports Strong First Quarter 2025 Financial Results
From Schrödinger
Via Business Wire
Schrödinger to Present at BofA Securities 2025 Healthcare Conference
From Schrödinger
Via Business Wire
Schrödinger Presents New Preclinical Data at AACR Annual Meeting
From Schrödinger
Via Business Wire
Schrödinger to Announce First Quarter 2025 Financial Results on May 7
From Schrödinger
Via Business Wire
Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Schrödinger
Via Business Wire
Schrödinger’s Statement Regarding FDA Plan to Phase Out Animal Testing Requirement for Monoclonal Antibodies and Other Drugs
From Schrödinger
Via Business Wire
Schrödinger to Present Preclinical Data at AACR Annual Meeting
From Schrödinger
Via Business Wire
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.